Review top news and interview highlights from the week ending January 12, 2024.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive™ team.
The associate professor at Fred Hutch Cancer Center discussed data from a retrospective analysis of patients treated with tisa-cel, axi-cel, or liso-cel.
In terms of safety, Descartes-08 was characterized as well-tolerated during the study and long-term follow-up period.
The clinical associate professor at Stanford Medicine also discussed ongoing trends in sickle cell disease research.
Exa-cel was recently approved for the treatment of SCD in the US, but data from the pivotal clinical trial continues to be collected.